This proposal is a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Medical School-Mayo Clinic. Clinical Pharmacology is the study of the interaction between therapeutic agents and humans. However, in the context of the ongoing """"""""Genomics Proteomics Revolution"""""""" in biomedical science, Clinical Pharmacology represents an important interface between basic molecular genetic, Genomic and proteomic science and rational therapeutics. Bridge disciplines such as Clinical Pharmacology are uniquely poised to take advantage of the revolution in biomedicine to apply this new scientific information at the translational interface in order to provide an understanding of the molecular basis for human response to drug therapy. However, the ability to take advantage of this unique opportunity will require the training of a new generation of Clinical Pharmacologists who are thoroughly grounded in basic molecular science and who are able to apply that science to study the interaction between patients and drugs. At this point in the Genomics-Proteomics Revolution, large comprehensive, integrated academic medical centers like the Mayo Clinic represent ideal locations for the training of this new generation of Clinical Pharmacologists. Mayo is positioned to accept this challenge because its basic science and clinical research programs are highly integrated, because it has a long history of contribution to the discipline of Clinical Pharmacology and because the Mayo Clinical Pharmacology Training Program has already had a decade of experience in successfully recruiting and training academic physicians who wish to apply biological science to Clinical Pharmacology. Fellowship Training that will emphasize a strong laboratory-based scientific experience, exposure to clinical science and highly structured and accountable mentorship is at the heart of the Mayo Clinical Pharmacology Fellowship Training Program described in this proposal.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008685-09
Application #
7085440
Study Section
Special Emphasis Panel (ZGM1-BRT-2 (PD))
Program Officer
Okita, Richard T
Project Start
1998-07-01
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
9
Fiscal Year
2006
Total Cost
$264,100
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ahmed, Ahmed T; Frye, Mark A; Rush, A John et al. (2018) Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. J Affect Disord 238:1-7
Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi et al. (2018) Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 9:1739
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Ahmed, Ahmed T; Weinshilboum, Richard; Frye, Mark A (2018) Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. Clin Pharmacol Ther 103:767-769
Cairns, Junmei; Fridley, Brooke L; Jenkins, Gregory D et al. (2018) Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation. EMBO Rep 19:
Kohorst, Mira A; Warad, Deepti M; Nageswara Rao, Amulya A et al. (2018) Obesity, sedentary lifestyle, and video games: The new thrombophilia cocktail in adolescents. Pediatr Blood Cancer 65:e27041
Eugene, Andy R (2017) CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol 6:242-249
Eugene, Andy R; Masiak, Jolanta (2017) A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nord J Psychiatry 71:417-424
Elraiyah, T; Jerde, C R; Shrestha, S et al. (2017) Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther 101:382-390

Showing the most recent 10 out of 61 publications